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Abstract
1 1Objective: Experiments were performed to examine the effect of chronic inhibition of the Na /H exchanger isoform-1 (NHE-1) on
cardiac hypertrophy of spontaneously hypertensive rats (SHR). Methods: SHR were orally treated during 1 month with two different
doses (0.3 and 3.0 mg/kg/day) of the NHE-1 inhibitor, cariporide, or nifedipine (10.0 mg/kg/day). Results: The two doses of cariporide
did not differ in their effects after 1 month of treatment, since both induced a slight decrease in systolic blood pressure (SBP) of |6
mmHg and regression of the heart weight to body weight ratio (mg/g) from 3.2860.05 to 3.0460.05 (0.3 mg) and 2.9960.10 (3.0 mg,
P,0.05). Nifedipine, given for the same period, produced similar reduction in the hypertrophy index (3.0360.05), but with a much
greater decrease in arterial pressure (35.667.4 mmHg). Chronic treatment with cariporide induced a complete regression of the
augmented cross sectional area of left ventricular myocytes without significant changes in collagen content, serum procollagen 1
propeptide levels or myocardial distensibility. Conclusions: NHE inhibition represents a novel approach to induce regression of
pathological hypertrophy of the heart. The finding can be rationalized mechanistically by previous in vitro studies suggesting a role of the
NHE in the development of myocardial hypertrophy.  2002 Elsevier Science B.V. All rights reserved.
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1. Introduction Sadoshima et al. [5]. Experiments performed in isolated
neonatal rat cardiac myocytes have further demonstrated
Mechanical stretch is one of the most important stimuli that ET-1 could also be detected in the cardiomyocyte
leading to cardiac hypertrophy. One of the earliest events culture medium 10 min after stretch [6]. The activation of
detected after stretching adult cardiac muscle is an en- MAP kinases and protein synthesis can be attenuated by
1 1hanced activity of the Na /H exchanger (NHE) [1]. The inhibition of the NHE when promoted by stretch, but not
stretch-induced activation of the NHE is the result of an after the addition of Ang II or ET-1 [7]. Furthermore, an
autocrine /paracrine chain of events involving the release enhanced activity of the NHE in the hypertrophied
of angiotensin II (Ang II) and endothelin (ET) [2–4]. The myocardium of the SHR [8,9] and the normalization of
release of these transmitters by stretching isolated neonatal NHE activity after enalapril-induced regression of cardiac
myocytes has been recognized since the seminal paper by hypertrophy [10] have been reported.
The mechanism by which mechanical stretch transmits
signals to the nucleus is not completely clarified. It
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of the NHE in a parallel and independent fashion. If so, the for determining collagen volume fraction (CVF) or 0.32
2enhanced activity of the NHE would be an epiphenomenon mm /pixel for determining the cross-sectional area of
of the hypertrophy and chronic inhibition of the NHE cardiac muscle cells. Fifty cross-sectioned cardiac muscle
should not be accompanied by a regression of myocardial fibers were counted in at least 10 images obtained from
hypertrophy. In order to shed light on this crucial issue, each left ventricle. Only round to ovoid cells with visible
experiments were performed in SHR in which the effect of round nucleus were considered for CSA measurements.
chronic inhibition of the NHE on myocardial hypertrophy Each cell was individually traced and its cross sectional
was assessed. area directly determined. CVF was calculated as the sum
of all connective tissue areas of the coronal sections,
divided by the total surface of the section. Perivascular
collagen was excluded from this measurement. To separate
2. Methods the stained tissues from other objects, a color segmentation
was applied. The investigator responsible for the mor-
Experiments were conducted in accordance with the phological analysis was blinded as to each experimental
Guide for the Care and Use of Laboratory Animals (US group.
Department of Health and Human Service) with male SHR To assess myocardial stiffness, isolated left ventricular
and normotensive Wistar (NT) rats. From the age of 3 papillary muscles were mounted in a horizontal perfusion
months, systolic blood pressure (SBP) was determined by chamber between a force transducer (AEM801 SensorOne)
the tail-cuff method [11]. At the age of 4 months, mean and a fixed hook for isometric records. The muscles were
SBP values were 12161 (NT, n541) and 17761 mmHg superfused at a constant rate (5 ml /min) with a CO /2
2(SHR, n553). At this time, animals of each strain were HCO -buffered solution containing (mmol / l) 128.3 NaCl,3
randomly assigned to one of the following treatments: (a) 4.5 KCl, 1.35 CaCl , 0.35 NaH PO , 20.23 NaHCO , 1.052 2 4 3
0.3 mg/kg/day cariporide (specific NHE-1 inhibitor); (b) MgSO , 11.0 glucose, equilibrated with 5% CO /95% O4 2 2
3.0 mg/kg/day cariporide; (c) 10.0 mg/kg/day nifedipine; (pH|7.4). The preparations were stimulated by square
(d) no drug (control untreated group) and (e) sacrifice to pulses of 5 ms duration, at a voltage |20% higher than the
assess the degree of cardiac hypertrophy at the time of threshold. After mounting, the values of muscle slack
treatment initiation. While cariporide was dissolved direct- length (L ), thickness and width were determined with a0
ly in the drinking water, nifedipine was orally administered reticle in the eyepiece of an SZ30 Olympus Zoom
in a single daily dose. The concentration of cariporide in stereomicroscope set at a total magnification of 330. The
the drinking water was adjusted according to weekly muscles were progressively stretched to the length at
measurements of BW and daily records of water intake to which they developed the maximal twitch force (L ) inmax
match with the selected dosages. After 1 month, the rats steps of 10% of L . The force was normalized to the cross0
were euthanized under ether anesthesia. Papillary muscles sectional area of each muscle, which was calculated
isolated from the left ventricle were used to assess multiplying thickness by width and corrected by a factor of
myocardial stiffness. After trimming off all adjacent 0.75 assuming an ellipsoidal shape. The stress–strain
connective tissue and the atria, the ventricles were blotted relationship for each muscle was fitted to an exponential
and weighed (HW) to determine the level of cardiac equation. From the fitted curves, fixed values of strains
hypertrophy by HW normalized to BW (HW/BW ratio, in (DL /L ) were interpolated in each experiment.max
mg/g). The ventricular tissue was fixed in buffered To determine serum levels of carboxyterminal prop-
formaldehyde 10% for 24 h. Coronal sections obtained eptide of procollagen type I (PIP), blood samples were
from the equator of the left ventricle were prepared for obtained at the time of euthanasia and allowed to clot
conventional histological techniques. Five-mm-thick paraf- spontaneously. After centrifugation, serum samples were
fin-embedded sections were stained either with Mallory’s separated and stored at 270 8C until assayed. Serum PIP
phosphotungstic acid hematoxylin (PTAH) method or a was determined by radioimmunoassay with a commercial
trichromic technique including Gill haematoxylin, xylidine assay kit (Orion Diagnostica, Finland). The lower de-
punceau and picric acid to differentiate fibrils and delineate tection limit (method sensitivity) was 1.2 mg/ l.
cell borders [12]. The trichrome Van Gieson stain tech-
nique was used for determining collagen in the muscle
tissue [12]. All the stained sections were observed under
the microscope (Olympus BX-50, Tokyo, Japan) and the 2.1. Statistics
images were captured using an analog video camera.
Images were digitized and processed by a computer Data were expressed as mean6S.E.M. One-way
morphometry program (Image-Pro Plus for Windows 95/ ANOVA and two-way ANOVA were used to compare
98 v4.5—Media Cybernetics, Silver Spring, MA, USA). differences, as appropriate. Dunnett was used as post hoc
The resolution of the microscopic images was of 6403480 test. P values ,0.05 were considered to indicate signifi-
2pixels with a spatial calibration yield of 0.63 mm /pixel cant differences.
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3. Results
SHR and their normotensive (NT) control rats were
treated orally with two doses of the specific inhibitor of the
NHE-1, cariporide, during 1 month. Fig. 1 shows the SBP
values during this time. A slight decrease in arterial
pressure following the treatment was detected in the SHR,
and no effect was evident in the NT rats. The two doses of
the inhibitor did not differ in their effect on blood pressure.
On average, the value of systolic arterial pressure at the
end of the treatment period was |6 mmHg lower in the
treated SHR than in the untreated animals. We did not Fig. 2. Effect of NHE-1 inhibition on cardiac hypertrophy in SHR.
Cardiac hypertrophy was assessed by HW/BW ratio in 4 months oldexplore the mechanism involved in this slight effect on
untreated SHR (n510); low-dose (0.3 mg/kg/day) cariporide-treatedSBP in the SHR rats. We speculate that the effect of the
SHR (Low-dose SHR-cari, n515); high dose (3.0 mg/kg/day)NHE inhibitor on cell growth might decrease wall thick- cariporide-treated SHR (High-dose SHR-cari, n56); nifedipine-treated
ness in resistance vessels of SHR [13]. SHR (SHR-nife, n56) and 5 months old untreated SHR (n517) rats.
The degree of cardiac hypertrophy was assessed by the Cariporide, at both dosages used, decreased cardiac hypertrophy in SHR
either compared with HW/BW values at the time of treatment initiation orHW/BW ratio. Fig. 2 shows the decrease in HW/BW
of age-matched untreated SHR rats. Interestingly, cariporide producedratios induced by treating SHR with cariporide, at both
about the same decrease in cardiac hypertrophy as nifedipine, despite adosages used, either when comparison was made with much lesser decrease in SBP. *Indicates P,0.05 between treated and
age-matched untreated SHR or with 4 months old SHR. untreated groups (ANOVA).
Chronic treatment with cariporide for 1 month did not
modify the HW/BW ratio in NT rats at any of the dosages
used. In cariporide-treated NT, HW/BW (mg/g) ratio were
2.4760.14 (n54) and 2.5660.10 (n57) after 1-month (2.5160.08, n510) nor from age-matched untreated NT
treatment with the low- and high-dosage, respectively. rats (2.5060.09, n57).
These values did not differ from the HW/BW determined Chronic NHE-1 inhibition induced a slight decrease in
in untreated NT rats at the age of treatment initiation arterial pressure together with a partial regression of the
myocardial hypertrophy, thus making it interesting to
compare these two effects, namely the decrease in arterial
pressure and the decrease in myocardial hypertrophy
induced by the NHE-1 inhibitor, with those induced by a
primary antihypertensive pharmacological intervention
such as nifedipine blockade of calcium channels. Since the
effect of dihydropyridines on hypertensive myocardium is
well established [14–18] and this study was particularly
focused on the action of NHE-1 blockade, the experiments
with nifedipine were aimed only to compare the relation-
ship between the reduction in SBP and the degree of
cardiac hypertrophy regression achieved by both treat-
ments. A similar decrease in the degree of hypertrophy was
obtained with cariporide and nifedipine (Fig. 2) but with
an approximately sixfold greater decrease in SBP after
nifedipine-treatment (Fig. 1). The decrease in arterial
pressure was only 5.761.7 and 5.661.6 mmHg with the
low and high dose of cariporide, respectively, and
35.667.4 mmHg with nifedipine (P,0.05).
Fig. 1. SBP values in untreated and treated NT and SHR rats. -d- Fig. 3 shows the mean cross sectional area (CSA) of left
(untreated SHR, n517); -\- (low-dose cariporide-treated SHR, n515); ventricular cardiomyocytes in the myocardium of untreated-h- (high-dose cariporide-treated SHR, n56), -♦- (nifedipine-treated
age-matched NT and SHR, and cariporide-treated (low-SHR, n56), -s- (untreated-NT, n514); - - - (low-dose cariporide-treated
NT, n59), ? ? ? (high-dose cariporide-treated NT, n58) and -y- and high-dose) SHR rats. A decrease in cardiomyocyte
(nifedipine-treated NT, n56). Nifedipine treatment reduced SBP by |40 CSA by |30% was detected in the myocardium of the
mmHg in SHR and by |15 mmHg in NT. By contrast, cariporide, at both SHR after the 1-month treatment with the NHE-1 inhibitor
dosages used, only in the SHR caused a slight but statistically significant at both dosages. The CSA of the cardiomyocytes indecrease of SBP. *Indicates P,0.05 between treated-SHR groups vs.
† cariporide-treated SHR was not different from that ofuntreated-SHR (ANOVA); indicates P,0.05 between nifedipine-treated
and untreated NT rats (ANOVA). untreated age-matched NT rats.
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Fig. 4 shows representative photomicrographs of left
ventricular myocardium from untreated age-matched NT
and SHR, and cariporide-treated (low- and high-dose) SHR
rats. An enlarged CSA is observed in the myocytes of the
hypertrophied myocardium of untreated SHR in accord-
ance to the overall results shown in Fig. 3. The increase in
CSA was reversed by cariporide both with the low- and the
high-dose treatment.
Fig. 5 shows length–tension curves of isolated left
ventricular papillary muscles from untreated age-matched
NT and SHR, and cariporide-treated (low- and high-dose)
SHR rats. The muscles isolated from hypertensive hy-
Fig. 3. Cross sectional area (CSA) of left ventricular cardiomyocytes. pertrophied hearts were stiffer than those from the nor-
Mean values of CSA determined in age-matched untreated NT (closed motensive animals (shift to the left in the length–tension
bar, n54), untreated SHR (open bar, n54), low-dose cariporide-treated curve). Chronic treatment with the NHE-1 inhibitor, inSHR (hatched bar, n55) and high-dose cariporide-treated SHR (cross-
spite of its effects on HW/BW ratio and cardiomyocytehatched bar, n54) rats are shown. In SHR, NHE-1 inhibition reduced the
size, did not return the stiffness to control levels at anyCSA of the cardiomyocytes to a value not different from that found in NT
rats. dosage used. The collagen volume fraction in the left
Fig. 4. Representative microphotographs of the left ventricle of age-matched untreated NT (panel A), untreated SHR (panel B), high-dose cariporide-
treated SHR (panel C) and low-dose cariporide-treated SHR rats (panel D). Cells were stained with a trichromic technique including Gill haematoxylin,
xylidine ponceau and picric acid. Magnification 10003. Bar510 mm.
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Fig. 5. Length–tension relationship in left ventricle papillary muscles. The muscles were isolated from age-matched untreated NT (j, n58), untreated
SHR (d, n58), low-dose cariporide-treated SHR (m, n55) and high-dose cariporide-treated SHR (^, n57). Papillary muscles from untreated SHR
showed increased stiffness compared to NT rats. NHE-1 inhibition did not reduce the increased stiffness in SHR despite reduction in cardiac hypertrophy.
Inset: shows collagen volume fraction in left ventricle (LVCVF) determined in untreated NT (closed bar, n54), untreated SHR (open bar, n54), low-dose
cariporide-treated SHR (hatched bar, n55) and high-dose cariporide-treated SHR (cross-hatched bar, n54) rats are shown. The NHE-1 inhibition did not
modify the increased fibrosis of the SHR myocardium.
ventricle (LVCVF) of age-matched untreated NT, un- the extent of myocardial fibrosis in SHR [20], serum PIP
treated SHR, and the low- and high-dose cariporide-treated levels were determined in the normotensive, hypertensive
SHR is shown in Fig. 5, inset. The increase in LVCVF in and hypertensive rats treated with cariporide and these data
the myocardium of the SHR is in agreement with previous are shown in Fig. 6. The increased levels of PIP in the
reports [19,20]. The treatment with the NHE-1 inhibitor blood of SHR compared to NT rats are in agreement with
did not result in a significant change of the LVCVF. the previously reported value [20]. Neither low-dose nor
Since the increase in serum levels of carboxyterminal high-dose cariporide treatment resulted in a significant
propeptide of procollagen type I (PIP), a marker of change of PIP levels in SHR. These data are in agreement
collagen type I synthesis, has been shown to correlate with with the lack of regression of the increased stiffness and
LVCVF. Again, the possibility that it would be necessary
to have a longer duration of the treatment to obtain a
decrease in PIP should be considered, taking into account
that 20 weeks of treatment are required to decrease the PIP
levels with an ACE inhibitor [20].
4. Discussion
This is the first report to document regression of
myocardial hypertrophy by an orally administered specific
NHE-1 inhibitor. This effect was achieved with a slight
decrease of |6 mmHg from pretreatment SBP value
Fig. 6. Serum levels of the procollagen type I peptide (PIP) in age- whereas a similar reduction of hypertrophy induced by
matched untreated NT (closed bar, n59) and untreated SHR (open bar, nifedipine was accompanied by a decrease in arterial
n512), low-dose cariporide-treated SHR (hatched bar, n55) and high- pressure of |36 mmHg. Two recent reports, however,dose cariporide-treated SHR (cross-hatched bar, n55) rats are shown.
called attention to the effect of in vivo NHE inhibition byThe increased levels of PIP in SHR were not modified by the NHE-1
cariporide on cellular growth. The first one describes theinhibition.
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regression of vascular hypertrophy in the diabetic rat [21], and ET [2–4]. A role for endogenous ET-1 locally
and the second one shows the prevention of cardiomyocyte produced and secreted by cardiomyocytes in the mecha-
hypertrophy after myocardial infarction [22] at a dosage nism of Ang II-induced cardiac hypertrophy was proposed
similar to the lower one used in our study. [28].
Both the dosage and the duration of the cariporide Stretch-induced release of Ang II and its autocrine link
treatment used in the present experiments deserve some with myocyte hypertrophy was demonstrated by
consideration. A wide range of cariporide dosages have Sadoshima et al. [5] in isolated neonatal rat cardiac cells.
been used by different investigators, and ours were either In the same preparation, the group of Yamazaki showed
lower than [21,23] or similar to [22,24] those of some that whereas NHE inhibition partially attenuated the
previous reports. Although we did not measure circulating increase in protein synthesis and MAP kinases activation
cariporide levels, the effect to regress and prevent further promoted by stretch [7,29], it did not inhibit Ang II- and
increase in cardiac hypertrophy was evident. In addition, ET-1-induced activation of these kinases [7]. The in-
rskthe fact that similar effects were obtained with the two volvement of MAP kinase and p90 -dependent phos-
doses of cariporide used shows that this chronic treatment phorylation of the NHE in ET-1-induced stimulation of the
was close to, if not at, the maximal effect for decreasing antiporter was recently demonstrated by Moor and Fliegel
cardiomyocyte size. The possibility of tissue accumulation [30].
of the NHE-1 inhibitor should also be considered. We may speculate that if an enhanced activity of the
1The regression of the myocyte size was not accom- NHE were maintaining an augmented Na concentration,i
1panied by a significant regression of cardiac fibrosis over blockade of NHE-1 would restore the Na concentrationi
21 1 21the 1-month study. The histological staining technique and thereby, blunt Ca influx through Na /Ca ex-
21used does not distinguish between the different collagen change. The notion that the increase in Ca is a primaryi
fractions. However, the increased stiffness detected in the signal for cardiac hypertrophy is supported by numerous
papillary muscles of SHR suggests the possibility of studies [31–35]. Yamazaki et al. [36] suggested two
alterations in collagen cross-linking [25]. The duration of independent hypertrophic pathways, one elicited by me-
the treatment in this study was too short as to ascertain chanical stretch and linked to NHE activation and another
whether or not this pharmacological intervention would linked to Ang II or ET-1 without involvement of NHE
also decrease fibrosis, or induce a total regression of heart activation. Our experiments in multicellular preparations
weight. Results obtained with different antihypertensive from adult myocardium would support the contention that
treatments on hypertrophied myocardium suggest that the Ang II, ET-1 and NHE are all steps of a single chain of
myocyte and nonmyocyte cells grow independently of each events beginning with the release of Ang II and ending
1other and that myocyte size declines more rapidly than the with the increase in Na due to NHE activation by ET-1.i
1involution of collagen [26]. Actually, whereas regression The notion that an increase in intracellular Na leads toi
21of myocyte size was obtained after 6 weeks of anti- a secondary increase in Ca is supported by severali
1hypertensive treatment, no regression of collagen was studies [2,37,38]. Furthermore, the link between Na
observed at that time [27]. Since previous studies have influx, activation of PKC-d and ´, and hypertrophy has
shown that regression of collagen and normalization of PIP been previously suggested [39]. Although stretch-sensitive
levels can be achieved with extended treatment with other channels are apparently good candidates to be analyzed as
pharmacological interventions [19,20], it appears that regards their possible role in the mechano-transduction
longer treatments would be necessary to establish whether mechanism, they do not seem to play any role in this
a similar result could happen with cariporide. In this pathway [5,7].
regard, ongoing experiments blocking NHE-1 for longer In summary, we report a regression of the car-
periods will allow us to learn whether or not this novel diomyocyte hypertrophy in SHR after 1-month of NHE-1
pharmacological intervention is able to decrease myocar- blockade. This regression of myocyte size occurred with-
dial fibrosis and stiffness. out significant changes in the augmented serum PIP levels,
In order to discuss the possible mechanisms by which LVCVF and myocardial stiffness. These novel findings
the chronic blockade of the NHE-1 may induce the may help to find the way to develop new therapeutic
regression of cardiac hypertrophy it is necessary to review strategies for the treatment of cardiac hypertrophy.
the available data linking the enhanced activity of the
NHE-1 to hypertrophic mechanisms. In the first place, an
enhanced activity of the NHE-1 in the hypertrophied
myocardium of the SHR has been reported [8,9]. Also, the Acknowledgements
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